Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
LaunchSudo Biosciences Launches Phase 1 Trial for SUDO-550, a Novel TYK2 Inhibitor Targeting Neuroinflammatory Diseases.
Dec 02, 2024
CarmelBiotechnologyHealth CareTherapeuticsBiopharmaBiotechnology Research
Product Description
Sudo Biosciences has announced the dosing of the first participants in a Phase 1 clinical trial for SUDO-550, an allosteric TYK2 inhibitor aimed at treating neuroinflammatory diseases. This trial will evaluate the safety and efficacy of SUDO-550, advancing its potential as a treatment for conditions like multiple sclerosis and Alzheimer’s.
Company Information
Company
Sudo Biosciences
Location
Carmel, Indiana, United States
About
Sudo Biosciences is a clinical-stage biopharmaceutical company developing next-generation TYK2 inhibitors to transform the treatment of immune-mediated diseases. Its pipeline includes a potential first- and best-in-class, once-daily oral, brain-penetrant candidate for multiple sclerosis and other neuroinflammatory conditions, as well as a topical candidate for dermatologic diseases. Based in Carmel, IN and London, U.K., Sudo is advancing novel medicines designed to improve patient lives.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Sudo Biosciences ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
CarmelBiotechnologyHealth CareTherapeuticsBiopharmaBiotechnology Research